TY - JOUR
T1 - From the beaker to the body
T2 - Translational challenges for electrochemical, aptamer-based sensors
AU - Arroyo-Currás, Netzahualcoyotl
AU - Dauphin-Ducharme, Philippe
AU - Scida, Karen
AU - Chávez, Jorge L.
N1 - Publisher Copyright:
© 2020 The Royal Society of Chemistry.
PY - 2020/3/14
Y1 - 2020/3/14
N2 - The ultimate goal of implantable bioanalytical sensors is to enable the continuous and precise monitoring of clinically and physiologically important targets in the body for prolonged periods. Electrochemical, aptamer-based (E-AB) sensors already achieve this goal in a modular way, so far allowing the multihour in vivo monitoring of over half a dozen molecular targets without relying on their specific chemical reactivities. E-AB sensors achieve this modularity by employing nucleic acid aptamers as recognition elements, which can reversibly and selectively bind to molecular targets even in complex biological fluids such as unprocessed blood. However, the translation of the E-AB platform from bench-top, in vitro proof-of-concept demonstrations to truly relevant in vivo clinical applications still faces challenges, some of which are dependent on innovations in the fields of material sciences, interfacial chemistry, biomedical engineering and data management. In this review we critically discuss some of the challenges that the E-AB platform still needs to overcome before it can achieve full, unhindered translation to biomedical and clinical research, decentralized diagnostics and medical applications.
AB - The ultimate goal of implantable bioanalytical sensors is to enable the continuous and precise monitoring of clinically and physiologically important targets in the body for prolonged periods. Electrochemical, aptamer-based (E-AB) sensors already achieve this goal in a modular way, so far allowing the multihour in vivo monitoring of over half a dozen molecular targets without relying on their specific chemical reactivities. E-AB sensors achieve this modularity by employing nucleic acid aptamers as recognition elements, which can reversibly and selectively bind to molecular targets even in complex biological fluids such as unprocessed blood. However, the translation of the E-AB platform from bench-top, in vitro proof-of-concept demonstrations to truly relevant in vivo clinical applications still faces challenges, some of which are dependent on innovations in the fields of material sciences, interfacial chemistry, biomedical engineering and data management. In this review we critically discuss some of the challenges that the E-AB platform still needs to overcome before it can achieve full, unhindered translation to biomedical and clinical research, decentralized diagnostics and medical applications.
UR - http://www.scopus.com/inward/record.url?scp=85081743046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081743046&partnerID=8YFLogxK
U2 - 10.1039/d0ay00026d
DO - 10.1039/d0ay00026d
M3 - Review article
AN - SCOPUS:85081743046
SN - 1759-9660
VL - 12
SP - 1288
EP - 1310
JO - Analytical Methods
JF - Analytical Methods
IS - 10
ER -